Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Asciminib in Korean patients with Chronic Myeloid Leukemia CML in a prospective, open-label, multi-center observational study. The study focuses on understanding how Asciminib works in real-world clinical settings following its market approval, enrolling patients treated under usual clinical practice. Participants prescribed Asciminib by their physicians according to the locally approved label will be included in this study. The dosage and duration of Asciminib treatment will be decided by the investigators based on prescribing information. The study plans to enroll all patients prescribed Asciminib for two years after its market launch. During the study, researchers will monitor participants for adverse events and various molecular response rates at 12 and 24 weeks. Data on safety, including serious and unexpected adverse reactions, will be collected. Participants will be followed during their usual care, and no study drug will be dispensed by the sponsor. The total participation duration depends on clinical practice and monitoring schedules.
Actively Recruiting
Researchers are observing adults with primary hypercholesterolemia or mixed dyslipidemia who are prescribed Leqvio Pre-filled Syringe inclisiran sodium to assess its safety and effectiveness in routine clinical practice. This is a non-interventional post-marketing surveillance study required by Korean health authorities to monitor patients already receiving this treatment. Participants are adults 18 years or older who have been prescribed Leqvio according to approved guidelines, including those who have not reached LDL-C targets with statins or cannot tolerate statins. There is no treatment allocation or placebo the study enrolls patients who have already started Leqvio treatment. The study will track patients over a period of up to 15 months. Throughout the study, researchers will monitor adverse events and adverse drug reactions and measure changes in LDL cholesterol levels and lipid profiles at baseline, 3, 9, and 15 months. The study will also analyze how patients baseline characteristics and medication use affect outcomes. Participants will provide informed consent, and their safety and treatment responses will be regularly assessed during routine clinical visits.
Actively Recruiting
This research aims to gather safety and effectiveness information for patients with neovascular age-related macular degeneration nAMD who are prescribed brolucizumab. It is an open-label, multicenter, single-arm, observational post-marketing surveillance study conducted by Novartis Pharmaceuticals to monitor patients receiving this treatment in real-world settings. Participants prescribed brolucizumab according to approved local guidelines will be enrolled. The study observes patients over 12 weeks initially, with additional data collected at 24 weeks and optionally at 36 weeks. There is no randomization or placebo group, as this is an observational study focusing on those already receiving brolucizumab. During the study, researchers will collect safety information, including adverse events up to 12 weeks and beyond. They will also evaluate vision-related outcomes such as changes in visual acuity and retinal thickness at baseline and follow-up visits. Other data include treatment history, injection numbers, and disease activity. Participants will be monitored through clinical assessments over the study period, which may last up to 36 weeks.